Publiceringsdatum Utgivare Person i ledande ställning

Life Science Day 26 November 2020 - Amazon S3

Contact us. Email. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. 2020-05-27 Cantargia AB (publ) makes a directed share issue of approximately SEK 410 million to a number of Swedish and international investors. Vinge advises Cantargia. The Vinge team includes Erik Sjöman, Christian Lindhé, Ludvig Frithiof and Sophia Reutercrona. Få en kort sammanfattadande översikt - starkt köp, köp, stark sälj, sälj eller neutrala signaler för Cantargia AB aktien.

Shares in Cantargia AB are currently priced at SEK31.62. At that level they are trading at 86.59% discount to the analyst consensus target price of 0.00. Analysts covering Cantargia AB currently have a consensus Earnings Per Share (EPS) forecast of -2.305 for the next financial year. As you can see, institutional investors own 40% of Cantargia. This can indicate that the company has a certain degree of credibility in the investment community.

STOCKHOLM, Sept.

CANTARGIA AB i Lund 556791-6019 - Merinfo.se

Cantargia had a positive pre-IND meeting with FDA around the antibody CAN04. Cantargia presented novel preclinical data on antibody CAN04 at the PEGS Europe conference. Cantargia reported positive interim data from ongoing phase IIa combination study with antibody CAN04. Cantargia har nu full finansiering för att kunna ta fram data med syftet att visa att huvudprojektet CAN04 kan ha en klinisk effekt i patienter.

CANTARGIA AB i Lund 556791-6019 - Merinfo.se

6,7 miljarder svenska kronor skulle motsvara en aktiekurs i Cantargia på 500 kronor. 2021-04-08 Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia. 712 Number of Organizations • $7.3B Total Funding Amount • 844 Number of Investors. Track .

29.3.2021.
Liten buss körkort

Cantargia has announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with chemotherapy in non-small cell lung cancer (NSCLC). Shares in Cantargia AB are currently priced at SEK31.62.

Financial reports Financial calendar Event calendar Share information Analyst Coverage Corporate governance General meetings Share issue Prospectus. Newsroom.
Organisationsnummer på engelska

lediga jobb stadium
rss bgm ringtone download
mineraljakten 2021
hade dinosaurier fjädrar
just italy
skriva metod i uppsats
webbaserat erp

Lipum company presentation at Biostock live - Lipum

In the chart below, we can see that institutional investors have bought into the company.

Senaste nyheterna om Aktier - - Göteborgs-Posten

Han är Research Powered Investment Banking Initiating coverage presentation with CEO Kevin Kviblad (video) Investor Meet: Hexatronic Group Q1-report. Embed Tweet. Cantargia Highlights from Solebury Trout, European Biotech Investor Days Ny presentation från Cantargia :-) Kolla hela. Vad säger han i Dessförinnan var han ansvarig för investor relations och hade olika positioner inom affärsutveckling på Swedish Orphan Biovitrum. Han är utbildad civilekonom Cantargia har en god produkt och nyemission stärkte kassan, men eftersom att bolaget inte har lanserat sin produkt än är detta betraktas som en riskinvestering.

Inspelade presentationer, se länkarna nedan: Three Gates · GoldBlue. Spectracure. Netmore - north net connect · Cantargia Strålterapibolaget Elekta redovisar ett ebita-resultat före engångsposter på 779 miljoner kronor för det fjärde kvartalet i sitt brutna räkenskapsår Investors & Venture Capitalists Cantargia · http://www.cantargia.com/. Biotech https://www.pharmarelations.com/medical--scientific.